Market Research Blog

Immunochemistry analyzer are becoming more and more popular in the global clinical chemistry and immunoassay as these are proved to be very effective tool to diagnose cancer, hepatitis, illegal drugs, fertility problems, sodium levels, endocrine function, and the detection of blood clots.

There are approximately more than 180,000 immunochemistry analyzers were installed globally in 2013. Out of which only about 17-20% of these analyzers are installed in the United States. This statistic suggests that the markets like China, India, and Japan where there is lack of basic lab facility prevails are adopting this new technology .Also it’s been seen that the recurring consumable sales are a strong factor to segment growth.

Immunochemistry analyzers are instruments that automatically run tests on samples from patients to detect any number of biologically active substances .It is very important to know which analyzer to use as different analyzers have different analysis time, and need different reagents which make these instrument highly sophisticated. These analyzers are mainly being used in infectious disease testing, cancer, cardiac, and autoimmune diseases.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-9189

Immunochemistry Analyzer Market: Drivers and Restraints

Under the strong rules & regulation laboratories find it difficult to have good revenues. Thus it’s very important to find ways to sustain in such a cost-crunched environment. Due to the cost cutting in clinical lab fees, profitability per test is decreasing which makes it necessary for the laboratories to focus on the volume rather than the value. There is also heavy pressure for quality, error-free results to ensure patient satisfaction. This forces labs to lean toward more automated systems with effective workflow solutions.

In US, Laboratories are encouraged for automation due to the heavy influx of patients with insurance coverage. But with limited workforce in the clinical lab it’s difficult to manage the huge inflow of patients. On the other hand patients need prompt & error free results. Thus this scenario demands laboratories to seek the help of systems that have a high accuracy, with managing high growing volumes and also offer remote data acquisition capabilities. The automated analyzers working with barcode readers, rack detection systems, and sample/plate identification modules to avoid plate or sample switch.

Immunochemistry Analyzer Market : Overview

With the rapid technological advancement in healthcare industry the immunochemistry analyzer market is expected to grow at a healthy CAGR in the forecasted period (2015-2025).

Globally, the immunochemistry market represents approximately 40.1% of the global in vitro diagnostics (IVD) market. Immunochemistry is by far the largest segment by volume, mostly due to routine testing. It is primarily driven by growing access to healthcare.

Immunochemistry Analyzer Market : Region-wise Outlook

Depending on geographic region, global immunochemistry analyzer market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa.

Demand for immunochemistry analyzers is slowing in the US and Western and Eastern Europe. Europe’s challenges in this segment include laboratory consolidation in France and economically troubled Greece, Italy, Spain, and Portugal. China’s growing rural hospital market lacks basic diagnostics laboratory infrastructure and represents an untapped opportunity for affordable immunochemistry analyzers.

Immunochemistry Analyzer Market : Key Players

The market is fully fragmented with leading brands, such as Siemens, Abbott Diagnostics, Beckman Coulter, Ortho Clinical Diagnostics, Thermo Fisher Scientific Inc.  and F. Hoffmann-La Roche Ltd.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-9189

The report covers exhaustive analysis on:

Market Segments

Market Dynamics

Market Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies involved

Technology

Value Chain

Regional analysis includes

North America (U.S., Canada)

Latin America (Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

Asia Pacific (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Immunochemistry Analyzer Market:Segmentation

Immunochemistry analyzer market is segmented into following types:

Instruments

Reagents

Global immunochemistry analyzer Market, by Instrument Type

Instruments

Immunochemistry Analyzers

Chemiluminescence Immunoassay (CLIA) Analyzers

Immuno Fluorescence (IFA) Analyzers

Enzyme Immunoassay (EIA) Analyzers

Radioimmunoassay (RIA) Analyzers

Enzyme Linked Fluorescent Assay (ELFA) Systems

Multiplexed Assay Systems

Immunochemistry Stainers

Automated Stainers

Semi-Automated Stainers

Global Immunochemistry analyzer Market, By Application

Endocrinology

Oncology

Cardiology

Therapeutic Drug Development & Monitoring

Infectious Disease Testing

Drugs Of Abuse Testing

Others

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-9189

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint

The company delivers the key insights on the global cytotoxic drugs market in its upcoming report titled “Cytotoxic Drugs Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028”. In terms of revenue, the global Cytotoxic Drugs market is projected to register a CAGR of 0.9% over the forecast period, owing to various factors, regarding which the company offers detailed insights and forecast.

The Cytotoxic Drugs market is segmented based on product type, by drug type, by route of administration, end users and regions. By drug type, the Cytotoxic Drugs market is segmented into; Alkylating Agents, Antitumor Antibiotics, Antimetabolites, Plant Alkaloids and Others. The Antimetabolites segment is expected to account a high share in the Cytotoxic Drugs market, with a growth rate of 1.2% by 2028. The Alkylating Agents segment is expected to witness a sluggish growth in the global Cytotoxic Drugs market due to market response over the use of such drug.

Cytotoxic Drugs Market: Dynamics

The growth of the Cytotoxic Drugs market is directly related to increased prevalence of cancer and higher access to the cancer care industry across the globe. Cytotoxic drugs are first line of treatment through chemotherapy in most cancer cases. As the technology continues to advance in traditional methods, it betters the further improvement in treatments and outcomes coming out of such technology.

Cytotoxic drugs are prescribed in lower doses and they function as immune suppressants.  Cytotoxic drugs can be classified as disease-modifying anti-rheumatic drugs (DMARDs). Thus application of cytotoxic drugs in treatment of rheumatic diseases provides lucrative opportunity for these cytotoxic drugs manufacturers.

“To remain ‘ahead’ of your competitors, request for a sample” – https://www.futuremarketinsights.com/reports/sample/rep-gb-2515

However, there are numerous complications in the use in the cytotoxic drugs, which are meant to kill the entire cell or just disturb the DNA strand in order to stop the growth of cancerous cells. Most of the cytotoxic drugs are suspected to be carcinogenic, mutagenic and teratogenic in nature.

Easier availability of Cytotoxic Drugs to match the cancer care standards across the globe has led to changing clinical approach towards chemotherapy treatment. Generic cytotoxic drugs are enjoy higher demand and are well accepted in emerging markets as they are cost-effective and offer good quality. Reimbursements policies for Cytotoxic Drugs however varies from region to region. Availability of competitive alternate treatment options impact revenue growth of cytotoxic drugs market.

Cost of development of cytotoxic drugs is very high and has been increasing over past years. The main cause of cost increase is due to the various technical, regulatory and economic constraints imposed during the development process of a cytotoxic drug.

The cytotoxic drugs market is experiencing a stable growth, which happens to be because of many related causes. One of the influences being growth of outsourcing manufacturing of cytotoxic products in order to balance the cost breakdown. The parallel growth of API market supports this trend. In response, contract manufacturers and developers like CDMOs are coming up with their knowledge and efficiency in order to strengthen the development of APIs and form a relation with parent organization helps the Cytotoxic Drugs market.

Cytotoxic Drugs Market: Geographical Insights

Cytotoxic Drugs report assesses the trends that are driving the growth of each segment on the global as well as regional level, and offers potential takeaways that could prove substantially useful for the manufacturers planning to enter the market.

Geographically, the global Cytotoxic Drugs market is segmented into North America, Western Europe, Eastern Europe, Latin America, Asia Pacific excluding China & Japan, China, Japan and Middle East & Africa. This report assesses the trends driving each segment and offers analysis and insights of the Cytotoxic Drugs market in specific regions. North America is expected to account the major share in the global Cytotoxic Drugs market and is expected to grow at a CAGR of 0.8%. APECJ is expected to have the highest growth rate of 1.3% for the global Cytotoxic Drugs market during the forecast period due to the growing number of cases and production facilities for small molecules APIs.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-2515

Cytotoxic Drugs Market: Key Players

Sanofi,

Pfizer,

Novartis AG,

Johnson and Johnson,

F. Hoffmann-La Roche AG,

Lonza,

Celgene Corp.,

Amgen Inc.,

GlaxoSmithKline PLC,

Merck & Co., Inc.,

Eli Lilly and Company and Teva Pharmaceutical.

In this cytotoxic drugs market report, we have discussed the individual strategies followed by cytotoxic drug manufacturers regarding the improvements in their products, creating new manufacturing facilities, market consolidation and advanced R&D initiatives. The cytotoxic drugs report has been concluded with key takeaways for players already present in the market and new players planning to enter the Cytotoxic Drugs market.

Key Segments

The report analyses the global Cytotoxic Drugs market based on the regions and presents the forecast in terms of value for the next 10 years. The regions covered in the report include:

North America

Latin America

Western Europe

Eastern Europe

APECJ

Japan

China

Middle East & Africa

The report analyses the global Cytotoxic Drugs market based on the product type and presents the forecast in terms of value for the next 10 years. The product types covered in the report include: 

Branded Drugs

Generic Drugs

The report analyses the global Cytotoxic Drugs market based on the drug type segment and presents the forecast in terms of value for the next 10 years. The drug type covered in the report include:  

Alkylating Agents

Antitumor Antibiotics

Antimetabolites

Plant Alkaloids

Others

The report analyses the global Cytotoxic Drugs market based on the Route of Administration segment and presents the forecast in terms of value for the next 10 years. The Route of Administration covered in the report include:  

Oral

Parenteral

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-2515

The report analyses the global Cytotoxic Drugs market based on the End User segment and presents the forecast in terms of value for the next 10 years. The End User covered in the report include:  

Hospital

Cancer Research Center

Drug Testing Laboratory

CDMOs

Sales of smart pill boxes and bottles are likely to reach around 800 thousand in 2019. According to a new analytical research study by Future Market Insights (FMI), smart pill boxes and bottles market will remain a high growth-low volume landscape over the course of next few years. Over 43% of total sales will be accounted by smart pill boxes. The report envisages a higher rate of adoption for smart pill bottles.

Almost 70% of adult patients are observed to discontinue or manipulate drug therapy, resulting in non-adherence to prescribed medication. The study opines that this directly adds to the economic burden on healthcare delivery system in form of emergency cases and hospitalization.

Smart pill boxes and bottles are increasingly being perceived as a potential solution to such challenges posed by increased healthcare delivery costs. Significance of medication adherence continues to rise with increasing prevalence of chronic conditions, propelling demand for smart pill boxes and bottles.

Dementia and geriatric care remain the key application areas of smart pill boxes and bottles, according to the report. More than 80% of sales is accounted by aging patients and dementia-afflicted population. Cancer management is likely to emerge lucrative in terms of applicability in coming years.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1710

With surging demand for high-quality healthcare delivery, senior care centers, hospitals, long-term care centers, and homecare settings are accelerating adoption of medication dispensers, thereby elevating the revenue growth of smart pill boxes and bottles market. Some of the leading companies are actively involved in the development of advanced technology medication dispensing devices with zero error risks during medication.

Home care settings maintain the highest consumption share in smart pill boxes and bottles market that roughly equates 65% of total sales. Almost a fifth of smart pill boxes and bottles sold are installed at seniors care and assisted living centers. FMI’s analysis indicates that long-term care centers are also creating promising market opportunities for smart pill boxes and bottles manufacturers and distributors.

North America continues to reign supreme owing to early adoption of advanced technology enabled smart pill boxes and bottles, accounting for more than a third of the global market revenue. European market for smart pill boxes and bottles also represents a substantial volume share, majorly driven by German patients. South and East Asian regions are briskly developing high-potential markets for manufacturers and distributors of smart pill boxes and bottles, says the report.

The vendor landscape of smart pill boxes and bottles market remains fairly consolidated and competitive, as Tier 1 manufacturers continue to account for a majority of share in the market in terms of volume. While dominance of Koninklijke Philips N.V., PharmRight Corporation & Livi, and AdhereTech prevails in smart pill boxes and bottles market, the report finds that the competition among these players is characterized by product innovation, new launches, and technological advancements.

FMI has tracked market performance for a decade-old projection period – 2018-2028. For exclusive insights on the various other aspects of smart pill boxes and bottles market landscape, write to the analyst at press@futuremarketinsights.com

key players featured in this report include

AdhereTech,

Koninklijke Philips N.V.,

MedMinder,

PharmRight Corporation & Livi,

Medipense Inc., e-pill,

LLC,

MedReady Inc.,

Pillsy, Inc.,

DoseSmart Inc,

SMRxT INC,

Pillo, Inc. and PillDrill, Inc.

Get a Customized Scope to Match Your Need Ask an Expert  @ https://www.futuremarketinsights.com/ask-question/rep-gb-1710

Key Segment

By product type

Smart Pill Box

Smart Pill Bottles

By indication

dementia

Parkinson’s disease

cancer management

diabetes care

geriatric care

disability

others

By end user

Seniors Care & Assisted Living

Long Term Care Centers

Home Care Settings

By regions

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East & Africa (MEA)

Additional Questions Answered

Some of the additional questions addressed in this report on the Smart Pill Boxes & Bottles market:

What is the overall revenue generation potential of the Smart Pill Boxes & Bottles market across the regions of Europe and South Asia?

Who are the key regional and global competitors? What are their portfolios in the Smart Pill Boxes & Bottles market?

What are the major challenges influencing the growth of the Smart Pill Boxes & Bottles market?

According to a study of Future Market Insights (FMI), anemia treatment market will surpass US$ 7.8 billion in 2019. More than 70% of the anemia treatment is sought for normocytic anemia, followed by microcytic anemia. Most of the demand for anemia treatment is driven by the condition as a result of one or more chronic diseases, according to a new research study by Future Market Insights.

One of the non-communicable chronic conditions responsible for the epidemiological transition of developing regions, chronic kidney disease (CKD) is a key factor fuelling demand for anemia treatment. Anemia treatment market is also receiving a strong impetus from the rising popularity of combination therapy. Increasing use of vitamin and iron supplements, antibiotics, metal chelating agents, and erythropoietin stimulating agents in combination therapy is cited as in important factor pushing prospects of anemia treatment market in upcoming years.

Key Players:

Amgen Inc.,

Hoffmann-La Roche Ltd,

Pfizer Inc.,

Novartis AG,

Janssen Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Ltd,

AMAG Pharmaceuticals,

Rockwell Medical, and Akebia Therapeutics,

among others.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8966

Vitamin Supplements Gains Significant Traction for Anemia Treatment

A surge in R&D investments is prominently improving scope of anemia treatment. Moreover, a rising number of pipeline drugs and promising potential of biosimilars will contribute to the demand for anemia treatment. However, high price point associated with biologics continues to mask their superior treatment efficacy over conventional medications.

More than 75% of anemia treatment market revenue is accounted by medications, of which, ESAs (erythropoietin stimulating agents) remain bestselling. Blood transfusion also cited as an important type of anemia treatment, contributing to the market growth. However, the demand for former is poised for a robust double-digit yearly growth in 2019 and ahead.

Lucrative emergence of ESAs and soaring consumption of other biosimilar medications are likely to introduce new investment opportunities in anemia treatment market. Extensive availability, accessibility, and economic price point of biosimilar drugs is strongly backed by an increasing number of FDA approvals. This according to FMI will significantly contribute in improvement of CKD, thereby bolstering the revenue of anemia treatment market. FDA recently issued an approval to a biosimilar drug by Pfizer for use in anemia treatment – Retacrit (epoetin alfa-epbx).

Over 55% of dietary supplements consumed as a part of anemia treatment are vitamin supplements. An increasing number of iron deficient patients will reportedly result in rapid demand growth of iron supplements in years to come, posing strong competition to that of vitamin supplements in the anemia treatment market. Currently, almost 60% of the medications and dietary supplements for anemia treatment is available at institutional pharmacies. The report also points to a gradually expanding share of retail pharmacies in the near future.

Just-under a third of the global demand for anemia treatment is raised by North American patients, whereas more than a third of the total demand is accounted collectively by East and South Asia. Europe is also cited as one of the key regional markets for anemia treatment providers.

Get a Customized Scope to Match Your Need Ask an Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-8966

Anemia Treatment Market: Additional Questions Answered

Some of the additional questions addressed in this report on the anemia treatment market”

What is the revenue potential of the anemia treatment markets across North America and Europe?

Who are the key competitors and what are their portfolios in the anemia treatment market?

What are the major challenges influencing the growth of the anemia treatment market?

How is intervention from regulatory authorities shaping the growth of the anemia treatment market?

Product-based Business Models Emerge as a Key Competitive Strategy

The consistent quest for therapeutically effective ESAs, dietary supplements, antibiotics, and other biologics to be used in anemia treatment continues to create attractive avenues in the R&D realm. Leading drug manufacturers are investing efforts in launching novel products and upgrading their existing consumable product portfolios. Amgen’s epoetin alpha has been a breakthrough product since its launch in the CKD treatment landscape and growing adoption continues to benefit the company.

Besides augmenting R&D investments, prominent players in anemia treatment market are also focusing on strategic agreements and partnerships – further paving the way for development of anemia treatment drugs. Emergence of partnership-based models in the competitive landscape of anemia treatment market is likely to reshape R&D structure in the anemia treatment market. The report prompts at major investment opportunities arising in open collaboration strategies. A number of drug manufacturers are also opting for partnerships with regional distribution leaders to form effective product-based distribution channels, particularly targeting developing regional markets.

Key Segment

Based on treatment, the anemia treatment market is segmented into

medications

dietary supplements

Based on disease, the anemia treatment market is segmented into

normocytic anemia

microcytic anemia

macrocytic anemia

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-8966

Future Market Insights delivers key insights on the global wearable sleep tracker market in its upcoming report titled “Wearable Sleep Trackers Market: Global Industry Analysis 2017 – 2021 and Opportunity Assessment 2022 – 2028”. In terms of revenue, the global wearable sleep tracker market is projected to register a CAGR of 7.6% over the forecast period, owing to various factors, regarding which FMI offers detailed insights and forecasts in this report.

The global wearable sleep tracker market is segmented based on product type, application, distribution channel and regions. Based on product type, the global wearable sleep tracker market is segmented into wearable sleep tracker ring devices, wearable sleep tracker wristband and hand band devices, wearable sleep tracker headband devices and sleep mask tracker devices. The wearable ring devices is expected to be the leading segment in the global wearable sleep tracker market, and is projected to grow at a CAGR of 9.5% over the forecast period.

Based on application type, the global wearable sleep tracker market is segmented into insomnia, sleep apnoea and others. The others segment (including wellness application) in the global wearable sleep tracker market is expected to account a high revenue share and grow at a CAGR of 7.1% over the forecast period. Based on distribution channel, the global wearable sleep tracker market is segmented into pharmacy and retails stores, online sales, hypermarkets and supermarkets and others. The online sales in the global wearable sleep tracker market is expected to be the leading segment, and is expected to grow at a CAGR of 7.9% over the forecast period.

“To remain ‘ahead’ of your competitors, request for a sample” – https://www.futuremarketinsights.com/reports/sample/rep-gb-6007

Major Key Players :

Fitbit Inc.

Garmin Ltd.

Huami Corporation

Fossil Group Inc

Koninklijke Philips N.V

Others

The growth of the global wearable sleep tracker market is primarily driven by increasing incidence of sleep disorders such as insomnia and sleep apnoea globally, availability of different types of wearable sleep trackers and growing awareness regarding sleep-related ailments and importance of a healthy sleep. Likewise, the number of new cases of sleep disorders have increased globally owing to the rise in obese and geriatric population and increase in unhealthy habits leading to unhealthy lifestyle. Different types of wearable sleep tracker devices are present in the market with different price ranges and fitness requirements. Besides, awareness regarding healthy sleep is also growing due to several educational programs and availability of information on the internet on conditions such as insomnia and sleep apnoea. Several sleep foundations such as the National Sleep Foundation are consistently spreading awareness regarding sleep disorder symptoms, diagnosis and treatments available.

There is a consistent growth in the healthcare expenditure in developed regions such as North America, Western Europe and Japan owing to increased incidence and prevalence of health-related problems and sleep disorders. Besides, growth in disposable income has contributed to an increase in wellness penetration, which has led to the growth of the market for wearable sleep tracker. Improved wearable sleep tracker technologies and better aesthetics are also expected to drive the growth of the wearable sleep trackers market over the forecast period.

This report assesses the trends that are driving the growth of each segment of the wearable sleep tracker market on the global as well as regional level, and offers potential takeaways that could prove substantially useful to the manufacturers planning to enter the wearable sleep tracker market.

North America accounted a high revenue share in 2017 and is expected to be the dominant regional market for wearable sleep tracker over the forecast period. The U.S. wearable sleep tracker market is expected to hold a large share in North America and is expected to grow at a CAGR of 5.1% over the forecast period. China and Asia Pacific excluding China & Japan wearable sleep tracker markets are anticipate to exhibits with double digit CAGRs over the forecast period.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-6007

Examples of some of the key players covered in the report of the wearable sleep tracker market are Fitbit, Inc., Garmin Ltd., Koninklijke Philips N.V., Huami Corporation, Fossil Group, Inc., and Huawei Technologies Co., Ltd., among others. The companies are focusing on developing novel wearable technologies. However, the higher cost associated with certain wearable sleep trackers and lack of standardization of these devices might hinder the growth of the wearable sleep trackers market over the forecast period.

In this report, we have discussed the individual strategies followed by these companies regarding the improvements in their products, creating new manufacturing facilities, market consolidation and advanced R&D initiatives. The report has been concluded with the key takeaways of the players present in the market and the new players planning to enter the market.

What is COVID-19 Impact on wearable sleep tracker market?

The Covid-19 pandemic has created varied effects on the wearable sleep tracker market. While the initial days of the pandemic in 2020 were characterized by supply chain disruptions, travel restrictions while being within the home, the market has now effectively contended with these disruptions. The wearable market supply has been affected by the novel coronavirus (COVID-19) outbreak, while on the other hand, it majorly impacted the online sales for sleep tracking devices in a positive manner. This is due to increased preference and usage of online shopping by the public. The larger take away for the market is now in terms of consumption patterns and demand for wearable sleep tracker in terms of products that are sought after.

Wearable Sleep Tracker Market by Category

By Product

Wearable Ring Devices

Wearable Wrist and Hand band Devices

Wearable Headband Devices

Sleep Mask Tracker Devices

By Application

Insomnia

Sleep Apnea

Others

By End User

Pharmacy and Retail Stores

Online Sales

Hypermarkets and Supermarkets

Others

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-6007

By Region

North America

Western Europe

China

Japan

Asia-Pacific Exc.C&J

Latin America

Eastern Europe

Middle East and Africa

According to the latest report published by Future Market Insights, titled ‘Global Injectable Drug Delivery Market: Global Industry Analysis 2013–2017 and Opportunity Assessment, 2018–2028’, the Global injectable drug delivery market is expected to expand at a CAGR of 10.9% over the forecast period, 2018–2028.

FMI estimates that the global market for injectable drug delivery was valued at US$ 10,400.0 Mn in 2017 and is expected to expand at CAGR of 10.9% over 2018–2028, to reach US$ 32,136.9 Mn by 2028 end. Based on product type, the needle-free injectable drug delivery segment dominated the global injectable drug delivery market in 2017. Moreover, the subtype, prefilled of needle-free injectors segment is expected to have a dominant share of the needle-free type of injectable drug delivery market due to its ease of application. North America is expected to maintain its dominance in the global injectable drug delivery market due to the presence of a large number of manufacturers of injectable drug delivery devices, mostly operating from the U.S.

Increase in prevalence of chronic diseases such as diabetes, cancer and rheumatoid arthritis along with other factors such as need for patient-controlled drug release and increased risk of needle stick injuries are the prominent factors expected to drive the growth of the injectable drug delivery market. Technological advancements have resulted in better product offerings in the injectable drug delivery market. However, some factors such as strict regulatory framework and premium pricing of products are expected to hinder the growth of the injectable drug delivery market. The key trend of the injectable drug delivery market is the increasing demand for point-of-care devices. Injectable drug delivery devices are easy to self-administer and do not require a healthcare professional for administration, which as a result skips the need of hospital visits and relatively lowers the healthcare spending for an individual.

“To remain ‘ahead’ of your competitors, request for a sample” – https://www.futuremarketinsights.com/reports/sample/rep-gb-393

The global injectable drug delivery market has been segmented on the basis of product type, usage, end users and regions. The disposable injectable drug delivery segment is expected to be the most attractive usage segment. Among the three end users, the hospital pharmacies is expected to be the dominant segment due to benefits such as favourable reimbursement policies in most of the countries across the globe.

In terms of value, the global injectable drug delivery market is expected to expand at 10.9% CAGR over the forecast period. With nearly 32% market share, North America was a dominant regional market for injectable drug delivery in 2017, due to growing number of manufacturers in the region and early adoption of new technologies. Western Europe is expected to be the second large market in injectable drug delivery, with Germany, the U.K. and France occupying major shares. APEJ is expected to be third large market for injectable drug delivery, due to requirement of low capital for manufacturing injectable drug delivery.

Key Research Findings

Increase in demand for point-of-care devices and reduced reliance on healthcare facilities are driving the growth of the global injectable drug delivery market

North America will be the dominant regional market for injectable drug delivery devices due to early adoption of advanced technologies

Most of the major players operate from the U.S., which makes the U.S. the leading market for injectable drug delivery devices in North America

In Europe, a large number of diabetes patients are switching towards needle-free injectable drug delivery devices from conventional injections since it is a painless process and reduces the risk of needle stick injuries

Disposable injectors are the most commonly available type of injectors since they are user friendly and do not require special skills for administration

Prefilled needle-free injectors are the most preferred type of injectors since they are much easier to administer than the fillable type

Price control for most of the injectable drug delivery devices is fierce. For instance, Mylan was pressurised to launch the generic version of the EpiPen to reduce the price of the product in the market. However, this has declined the revenue of the company.

In developed regions, such as North America and Europe, hospitals are the dominant distribution channel due in injectable drug delivery due to the reimbursement policies

The growing competition in the emerging market and the rising demand for injectable drug delivery are the future opportunities for the growth and expansion of the injectable drug delivery market.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-393

Examples of some of the key players identified in the global injectable drug delivery market include:

Amgen Inc.,

Medtronic PLC,

West Pharmaceutical Services,

Yepsomed, Becton, and Dickinson And Company,

Antares Pharma,

Mylan,

SHL Group,

Endo International PLC,

Crossject, and Consort Medical (Bespak),

among others.

Injectable Drug Delivery Market – Key Segments Covered

The Global Injectable Drug Delivery Market has been Segmented Based on:

Product Type

Usage

Distribution Channel

Regions

The Injectable Drug Delivery Market report classifies the regions and presents the forecast in terms of value for the next 10 years. The regions covered in the report include:

North America

Eastern Europe

Western Europe

Latin America

Asia Pacific except Japan (APEJ)

Japan

Middle East and Africa (MEA)

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-393

The next section of the Injectable Drug Delivery Market report analyses the product type and presents the forecast in terms of value for the next 10 years. The injectable drug delivery types covered in the report include:

Self-Injectors

Needle-free Injectors

Auto-Injectors

The next classification is based on usage of injectable drug delivery products and provides forecast in terms of value for the next 10 years. The usages covered in this report include:

Disposable Injectors

Reusable Injectors

The next classification is based on distribution channel of injectable drug delivery products and provides forecast in terms of value for the next 10 years. The distribution channels covered in this report include:

Hospital Pharmacies

Retail Pharmacies

E-commerce

ESOMAR-certified consulting firm Future Market Insights’ report, projects a steady growth of global halal nutraceutical & vaccines market. The report has forecast the market to reach a valuation of US$ 116381.3 Mn over the forecast period of 2021 and 2031.

Growing demand for halal dietary supplements from Muslim dominant countries is accelerating the demand of halal nutraceutical & vaccines across the globe.

Key players are investing heavily in order to adhere to the regulations of halal products to cater the demand. Initiatives undertaken and increased funding for the promotion of halal dietary supplements across Malaysia, UAE, Singapore and China will bolster the growth.

Development of halal products for vegetarian customers with the increasing prevalence of lifestyle disorders such as diabetes, obesity and others are propelling the demand for halal dietary supplements.

As per the FMI’s analysis, due to the high demand from the GCC countries, Indonesia and Malaysia for dietary supplements & other products, the market witnessed steady growth at 6.50% CAGR during 2016-2020.

However, high cost of production in compliance to the regulation of halal certification will impede the market growth. Less production and demand from the U.S, the U.K and other western countries might hamper the demand.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2703

Key Takeaways from FMI’s Halal nutraceutical & vaccines Market Study

By distribution channel, hospital pharmacies segment will remain highly sought-after for halal nutraceutical & vaccine sales.

In terms of application type, general wellbeing will retain its dominance, while immune & digestive health will account for second largest application

Halal dietary supplements will dominate the halal nutraceutical & vaccines market in terms of product over the forecast period

Indonesia and Switzerland will emerge as the leading market across Asia Pacific excluding Japan backed by the high demand of halal dietary supplements

UAE will emerge as the most lucrative market registering fastest growth in terms of value over the forecast period

Malaysia is anticipated to lead the Asia’s Halal nutraceutical & vaccines market, exhibiting the growth at 18.3% CAGR

Competitive Landscape

Prominent halal nutraceutical & vaccines market players profiled by Future Market Insights include Chemical Company of Malaysia Berhad, Abbott Laboratories, Nestle, Amway, Herbalife International of America Inc., AJ Biologics SDN BHD, Agropur Inc., PT Kalbe Farma TBK, Kotra Pharma SDN BHD, and Noor Vitamins among others.

Abbott Laboratories and Herbalife International of America, Inc. are two leading companies dominating the global halal nutraceuticals & vaccines market.

While Abbott Laboratories is expected to focus on producing halal nutraceutical & vaccines for infants, women and specific therapeutic nutrition, Herbalife is emphasizing its business measures more towards consumer awareness through promotional campaigns.

Multinational food & beverage companies like Nestlé S.A. and Amway are also increasing their presence in the global halal nutraceutical & vaccines market to gain competitive edge.

Chemical Company of Malaysia Berhad, AJ Biologics Sdn Bhd., Agropur, Inc., and Kotra Pharma (M) Sdn Bhd, are also recognized as the leading companies in the global halal nutraceutical & vaccines market.

Increasing initiatives for the certification of halal products and demand from Middle East countries are widening the growth opportunities for the leading players. Increasing demand for halal dietary supplements across Malaysia and Indonesia will broaden the future expansion prospects for the market players.

Get a Customized Scope to Match Your Need Ask an Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-2703

Halal nutraceutical & vaccines Market by Category

By Product Type:

Halal Dietary Supplements

Halal Vaccines

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Sales

Super Markets

By Application:

Sports Nutrition

General Wellbeing

Immune & Digestive Health

Bone & Joint Health

Heart Health

Disease Prevention

Weight Loss

By Region:

North America

Latin America

Eastern Europe

Western Europe

Asia Pacific excluding Japan

Japan

Middle East and Africa (MEA)

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-2703